Core Viewpoint - Novo Nordisk's oral GLP-1 weight loss drug Wegovy has received FDA approval, allowing the company to gain a competitive edge over Eli Lilly in the weight loss market [1][3]. Group 1: Product Launch and Pricing - The oral version of Wegovy will be launched in the U.S. in early January at a starting cash price of $149 per month, with potential costs as low as $25 for insured patients [5][6]. - The approval of the oral drug is seen as a crucial victory for Novo Nordisk, especially after concerns about its competitive position in the market [3][8]. Group 2: Clinical Data and Efficacy - Clinical trial results from the Oasis 4 study indicate that patients taking a daily dose of 25 mg lost an average of 16.6% of their body weight over 64 weeks, supporting the drug's efficacy [7]. - The drug is also approved to reduce the risk of major cardiovascular events in obese adults with cardiovascular disease, enhancing its competitive edge [7]. Group 3: Market Dynamics and Competition - The approval of the oral drug allows Novo Nordisk to temporarily lead in the competitive landscape against Eli Lilly, which is expected to receive approval for its own oral weight loss drug in March [3][8]. - The oral formulation is viewed as a key driver for future growth, especially as the market for weight loss drugs becomes increasingly competitive [8]. Group 4: Future Market Potential - The oral formulation is anticipated to be a significant growth engine in the weight loss drug market, with projections suggesting it could capture 24% of the global market by 2030, valued at approximately $22 billion [9]. - Convenience is a critical factor, as Novo Nordisk's oral drug requires patients to wait 30 minutes before eating or drinking, while Eli Lilly's oral drug may offer easier absorption without such restrictions [9].